Lisata Therapeutics Files Q3 2024 10-Q
Ticker: LSTA · Form: 10-Q · Filed: Nov 12, 2024 · CIK: 320017
Sentiment: neutral
Topics: 10-Q, financials, biotech
TL;DR
Lisata's Q3 10-Q is in. Check financials and ops updates.
AI Summary
Lisata Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported financial results and provided updates on its business operations. Specific financial figures and operational details are available within the full filing.
Why It Matters
This filing provides investors with the latest financial health and operational status of Lisata Therapeutics, crucial for understanding its current performance and future prospects.
Risk Assessment
Risk Level: medium — As a biotechnology company, Lisata Therapeutics operates in a high-risk, high-reward industry with significant regulatory and market uncertainties.
Key Players & Entities
- LISATA THERAPEUTICS, INC. (company) — Filer
- 20240930 (date) — Period of Report
- 20241112 (date) — Filing Date
- CALADRIUS BIOSCIENCES, INC. (company) — Former Company Name
- NeoStem, Inc. (company) — Former Company Name
FAQ
What is the reporting period for this 10-Q filing?
The Conformed Period of Report is 20240930, meaning the filing covers the period up to September 30, 2024.
When was this 10-Q filed with the SEC?
This 10-Q was filed on 20241112.
What was Lisata Therapeutics, Inc. previously known as?
Lisata Therapeutics, Inc. was formerly known as CALADRIUS BIOSCIENCES, INC. and before that, NeoStem, Inc.
What is the Standard Industrial Classification code for Lisata Therapeutics, Inc.?
The Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.
Where is Lisata Therapeutics, Inc. headquartered?
The company's business address is located at 110 Allen Road, Second Floor, Basking Ridge, NJ 07920.
Filing Stats: 4,639 words · 19 min read · ~15 pages · Grade level 18 · Accepted 2024-11-12 16:10:45
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share LSTA The Nasdaq Capital Marke
Filing Documents
- lsta-20240930.htm (10-Q) — 934KB
- lsta-ex311_20240930.htm (EX-31.1) — 9KB
- lsta-ex312_20240930.htm (EX-31.2) — 9KB
- lsta-ex321_20240930.htm (EX-32.1) — 7KB
- lsta-ex322_20240930.htm (EX-32.2) — 7KB
- lsta-20240930_g1.jpg (GRAPHIC) — 184KB
- 0000320017-24-000058.txt ( ) — 6474KB
- lsta-20240930.xsd (EX-101.SCH) — 45KB
- lsta-20240930_cal.xml (EX-101.CAL) — 58KB
- lsta-20240930_def.xml (EX-101.DEF) — 176KB
- lsta-20240930_lab.xml (EX-101.LAB) — 624KB
- lsta-20240930_pre.xml (EX-101.PRE) — 419KB
- lsta-20240930_htm.xml (XML) — 755KB
- FINANCIAL INFORMATION
PART I- FINANCIAL INFORMATION Page No. Item 1.
Financial Statements
Financial Statements: 5 Consolidated Balance Sheets at September , 30 2024 (unaudited) and December 31, 2023 5 Consolidated Statements of Operations for the three and nine months ended S e ptem ber 30, 2024 and 2023 (unaudited) 6 Consolidated Statements of Comprehensive Loss for the three and nine months ended S e ptember 30, 2024 and 2023 (unaudited) 7 Consolidated Statements of Equity for the three and nine months ended Sept ember 30, 2024 and 2023 (unaudited) 8 Consolidated Statements of Cash Flows for the nine months ended S e ptember 30, 2024 and 2023 (unaudited) 10 Notes to Unaudited Consolidated Financial Statements 11 Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 25 Item 3.
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk 31 Item 4.
Controls and Procedures
Controls and Procedures 31
- OTHER INFORMATION
PART II- OTHER INFORMATION Item 1.
Legal Proceedings
Legal Proceedings 33 Item 1A.
Risk Factors
Risk Factors 33 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 33 Item 3. Defaults Upon Senior Securities 33 Item 4. Mine Safety Disclosures 33 Item 5. Other Information 33 Item 6. Exhibits 33
Signatures
Signatures 34 4 Index
FINANCIAL INFORMATION
PART I. FINANCIAL INFORMATION
FINANCIAL STATEMENTS
ITEM 1. FINANCIAL STATEMENTS LISATA THERAPEUTICS, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (In thousands, except share data) September 30, 2024 December 31, 2023 ASSETS (Unaudited) Cash and cash equivalents $ 19,509 $ 22,593 Marketable securities 16,347 27,942 Prepaid and other current assets 1,836 3,389 Total current assets 37,692 53,924 Property and equipment, net 96 175 Acquired license - intangible, net 210 263 Other assets 201 332 Total assets $ 38,199 $ 54,694 LIABILITIES, NON-CONTROLLING INTERESTS AND STOCKHOLDERS' EQUITY Liabilities Accounts payable $ 556 $ 2,421 Accrued liabilities 4,135 4,169 Total current liabilities 4,691 6,590 Other long-term liabilities 72 210 Total liabilities 4,763 6,800 Commitments and Contingencies (Note 13) Stockholders' Equity Common stock, $ 0.001 par value, authorized 500,000,000 shares; issued 8,320,338 and 8,150,635 shares at September 30, 2024 and December 31, 2023, respectively; and outstanding, 8,319,600 and 8,149,897 shares at September 30, 2024 and December 31, 2023, respectively 8 8 Additional paid-in capital 577,878 576,971 Treasury stock, at cost; 738 shares at September 30, 2024 and December 31, 2023 ( 708 ) ( 708 ) Accumulated deficit ( 543,456 ) ( 528,081 ) Accumulated other comprehensive loss ( 32 ) ( 42 ) Total Lisata Therapeutics, Inc. stockholders' equity 33,690 48,148 Non-controlling interests ( 254 ) ( 254 ) Total equity 33,436 47,894 Total liabilities, non-controlling interests and stockholders' equity $ 38,199 $ 54,694 See accompanying notes to consolidated financial statements. 5 Index LISATA THERAPEUTICS, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (In thousands, except per share data) Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Operating Expenses: Research and development $ 2,542 $ 3,380 $ 8,384 $ 9,721 General and administrative 2,794 2,584 9,076 9,962 Total operatin